LRRK2-G2019S carriers have an increased cancer risk, in particular for brain, breast, colon and blood cancers and female gender was associated with a reduced risk of bladder colon, hematological, kidney, liver, lung, rectal, and stomach cancer. This evidence concerns the gene LRRK2 and gastric neoplasm.